Malignant Breast Neoplasm — Trials

Malignant Breast Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

12,355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,627
Recruiting: 1,396
Ph III recruiting: 150
Growth YoY: +22.2%
Industry share: 18%
Top sponsor: Fudan University
Termination share: 25.6%
Trials / 1,000 deaths: 61.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,367)

clinicaltrialsPublishedShowing 1–50 of 550 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03734029	Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]	completed	Phase 3	557	Daiichi SankyoINDUSTRY	20	Sep 28, 2026	clinicaltrials
NCT00553410	Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer(SOLE)	completed	Phase 3	4,884	ETOP IBCSG Partners FoundationNETWORK